PLX logo

Protalix BioTherapeutics (PLX) Accounts Payable

Annual Accounts Payable

$4.32 M
-$1.54 M-26.31%

December 31, 2023

Summary

Performance

1-Year Change

-26.31%

3-Year Change

-40.17%

5-Year Change

-17.1%

15-Year Change

-42.56%

PLX Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

51%
PLX annual accounts payable is higher than 51% of companies in Healthcare sector

High & Low

All-time High

$7.52 M
PLX annual accounts payable is currently -42.56% below its historical high of $7.52 million

3-Year Low

$4.32 M
PLX annual accounts payable is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
PLX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 14, 2025
PLX next annual earnings announcement is scheduled for Mar 14, 2025

OtherPLXbalance sheetmetrics:

Annual Accounts Receivable

$5.27 M
PLX annual accounts receivable is $5.27 million

Annual Total Liabilities

$50.87 M
PLX annual total liabilities is $50.87 million

Annual Total Assets

$84.43 M
PLX annual total assets is $84.43 million

Annual Current Assets

$69.93 M
PLX annual total current assets is $69.93 million

Quarterly Accounts Payable

$3.13 M
-$929.00 K-22.86%

September 30, 2024

Summary

Performance

3-Month Change

-22.86%

1-Year Change

+0.67%

3-Year Change

+0.67%

5-Year Change

+0.67%

PLX Quarterly Accounts Payable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

44.17%
PLX quarterly accounts payable is higher than 44.17% of companies in Healthcare sector

High & Low

All-time High

$12.68 M
PLX quarterly accounts payable is currently -75.28% below its historical high of $12.68 million

3-Year Low

$3.11 M
PLX quarterly accounts payable is currently +0.67% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PLX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
PLX next earnings announcement is scheduled for Mar 14, 2025

OtherPLXbalance sheetmetrics:

Quarterly Accounts Receivable

$2.19 M
PLX quarterly accounts receivable is $2.19 million

Quarterly Total Liabilities

$29.13 M
PLX quarterly total liabilities is $29.13 million

Quarterly Total Assets

$61.56 M
PLX quarterly total assets is $61.56 million

Quarterly Current Assets

$47.85 M
PLX quarterly total current assets is $47.85 million

Accounts Payable Formula

Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers

PLX Accounts Payable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-26.3%+0.7%
3 y3 years-40.2%+0.7%
5 y5 years-17.1%+0.7%

PLX Accounts Payable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-38.2%at low-60.2%+0.7%
5 y5-year-40.2%at low-66.8%+0.7%
alltimeall time-42.6%>+9999.0%-75.3%>+9999.0%

Protalix BioTherapeutics Accounts Payable History

DateAnnualQuarterly
Sep 2024
-
$3.13 M(-22.9%)
Jun 2024
-
$4.06 M(+29.2%)
Mar 2024
-
$3.15 M(-27.2%)
Dec 2023
$4.32 M(-26.3%)
$4.32 M(+38.7%)
Sep 2023
-
$3.11 M(-5.8%)
Jun 2023
-
$3.30 M(-35.3%)
Mar 2023
-
$5.11 M(-12.9%)
Dec 2022
$5.86 M(-16.1%)
$5.86 M(+4.0%)
Sep 2022
-
$5.64 M(-19.3%)
Jun 2022
-
$6.99 M(-11.2%)
Mar 2022
-
$7.87 M(+12.7%)
Dec 2021
$6.99 M(-3.3%)
$6.99 M(-17.2%)
Sep 2021
-
$8.44 M(+37.7%)
Jun 2021
-
$6.13 M(-3.9%)
Mar 2021
-
$6.38 M(-11.7%)
Dec 2020
$7.22 M(+11.2%)
$7.22 M(-13.5%)
Sep 2020
-
$8.35 M(+24.5%)
Jun 2020
-
$6.71 M(-28.9%)
Mar 2020
-
$9.43 M(+45.2%)
Dec 2019
$6.50 M(+24.6%)
$6.50 M(-16.2%)
Sep 2019
-
$7.75 M(+15.3%)
Jun 2019
-
$6.73 M(+14.6%)
Mar 2019
-
$5.87 M(+12.6%)
Dec 2018
$5.21 M(-30.7%)
$5.21 M(+18.8%)
Sep 2018
-
$4.39 M(-26.9%)
Jun 2018
-
$6.00 M(+23.2%)
Mar 2018
-
$4.87 M(-35.2%)
Dec 2017
$7.52 M(+87.7%)
$7.52 M(-13.5%)
Sep 2017
-
$8.69 M(+10.7%)
Jun 2017
-
$7.85 M(+30.9%)
Mar 2017
-
$6.00 M(+49.7%)
Dec 2016
$4.01 M(+10.4%)
$4.01 M(+0.5%)
Sep 2016
-
$3.99 M(+4.5%)
Jun 2016
-
$3.82 M(-1.8%)
Mar 2016
-
$3.89 M(+7.2%)
Dec 2015
$3.63 M(-5.4%)
$3.63 M(-10.5%)
Sep 2015
-
$4.06 M(-5.1%)
Jun 2015
-
$4.28 M(-17.7%)
Mar 2015
-
$5.20 M(+35.4%)
Dec 2014
$3.84 M(-27.0%)
$3.84 M(+7.2%)
Sep 2014
-
$3.58 M(-0.4%)
Jun 2014
-
$3.59 M(-22.6%)
Mar 2014
-
$4.64 M(-11.7%)
Dec 2013
$5.25 M(-0.2%)
$5.25 M(+58.6%)
Sep 2013
-
$3.31 M(-16.0%)
Jun 2013
-
$3.94 M(+4.8%)
Mar 2013
-
$3.76 M(-28.6%)
Dec 2012
$5.27 M
$5.27 M(+19.0%)
Sep 2012
-
$4.43 M(-1.9%)
DateAnnualQuarterly
Jun 2012
-
$4.51 M(-1.2%)
Mar 2012
-
$4.57 M(-9.2%)
Dec 2011
$5.03 M(-19.8%)
$5.03 M(-60.3%)
Sep 2011
-
$12.68 M(+116.9%)
Jun 2011
-
$5.85 M(-22.4%)
Mar 2011
-
$7.53 M(+20.1%)
Dec 2010
$6.27 M(+84.1%)
$6.27 M(+41.5%)
Jun 2010
-
$4.43 M(-18.4%)
Mar 2010
-
$5.43 M(+59.4%)
Dec 2009
$3.41 M(+52.4%)
$3.41 M(+80.1%)
Sep 2009
-
$1.89 M(-4.6%)
Jun 2009
-
$1.98 M(+16.1%)
Mar 2009
-
$1.71 M(-23.6%)
Dec 2008
$2.23 M(+148.6%)
$2.23 M(+8.1%)
Sep 2008
-
$2.07 M(+20.6%)
Jun 2008
-
$1.71 M(+62.2%)
Mar 2008
-
$1.06 M(+17.6%)
Dec 2007
$899.00 K(+0.8%)
$899.00 K(-33.8%)
Sep 2007
-
$1.36 M(+56.7%)
Jun 2007
-
$867.00 K(+10.0%)
Mar 2007
-
$788.00 K(-11.7%)
Dec 2006
$892.00 K(+109.4%)
$892.00 K(+7271.9%)
Sep 2006
-
$12.10 K(-10.4%)
Jun 2006
-
$13.50 K(-96.8%)
Dec 2005
$426.00 K(>+9900.0%)
$426.00 K(>+9900.0%)
Mar 2005
-
$4200.00(+5.0%)
Dec 2004
$4000.00(-94.9%)
$4000.00(-4.8%)
Sep 2004
-
$4200.00(-93.8%)
Jun 2004
-
$67.40 K(+9.4%)
Mar 2004
-
$61.60 K(-21.8%)
Dec 2003
$78.80 K(-0.4%)
$78.80 K(+24.7%)
Sep 2003
-
$63.20 K(+2.4%)
Jun 2003
-
$61.70 K(-23.9%)
Mar 2003
-
$81.10 K(+2.5%)
Dec 2002
$79.10 K(+2.3%)
$79.10 K(+20.9%)
Sep 2002
-
$65.40 K(+6.5%)
Jun 2002
-
$61.40 K(-12.4%)
Mar 2002
-
$70.10 K(-9.3%)
Dec 2001
$77.30 K(-84.1%)
$77.30 K(+28.4%)
Sep 2001
-
$60.20 K(+4.5%)
Jun 2001
-
$57.60 K(-90.5%)
Mar 2001
-
$606.70 K(+24.6%)
Dec 2000
$486.80 K(+48.6%)
$486.80 K(+65.2%)
Sep 2000
-
$294.70 K(+12.7%)
Jun 2000
-
$261.50 K(-10.2%)
Mar 2000
-
$291.20 K(-11.1%)
Dec 1999
$327.70 K
$327.70 K(-12.2%)
Sep 1999
-
$373.30 K(-6.3%)
Jun 1999
-
$398.20 K(-25.1%)
Mar 1999
-
$531.90 K

FAQ

  • What is Protalix BioTherapeutics annual accounts payable?
  • What is the all time high annual accounts payable for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics annual accounts payable year-on-year change?
  • What is Protalix BioTherapeutics quarterly accounts payable?
  • What is the all time high quarterly accounts payable for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics quarterly accounts payable year-on-year change?

What is Protalix BioTherapeutics annual accounts payable?

The current annual accounts payable of PLX is $4.32 M

What is the all time high annual accounts payable for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high annual accounts payable is $7.52 M

What is Protalix BioTherapeutics annual accounts payable year-on-year change?

Over the past year, PLX annual accounts payable has changed by -$1.54 M (-26.31%)

What is Protalix BioTherapeutics quarterly accounts payable?

The current quarterly accounts payable of PLX is $3.13 M

What is the all time high quarterly accounts payable for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high quarterly accounts payable is $12.68 M

What is Protalix BioTherapeutics quarterly accounts payable year-on-year change?

Over the past year, PLX quarterly accounts payable has changed by +$21.00 K (+0.67%)